Application value of liver transplantation for primary biliary cirrhosis

doi:10.3877/cma.j.issn.2095-3232.2017.05.014

Abstract

Abstract:

Objective

To investigate the application value of liver transplantation (LT) in the treatment of primary biliary cirrhosis (PBC).

Methods

Clinical data of 16 patients with PBC who underwent LT in the First Affiliated Hospital of Xi'an Jiaotong University Medical College between July 2006 and November 2016 were retrospectively analyzed. The informed consents of all patients were obtained and the local ethical committee approval was received. Among them, 4 cases were males and 12 females, aged (54±6) years old on average. Allogeneic modified piggyback orthotopic LT was performed in all patients. The general data, clinical symptoms, physical signs, laboratory test, intraoperative and postoperative conditions were observed. All patients received postoperative follow-up on a regular basis.

Results

Varying degrees of liver dysfunction and jaundice were observed in the patients before LT. Intraoperatively, 1 patient died from hemorrhagic shock and the remaining 15 cases successfully completed the surgery. The operation time was (378±67) min, the anhepatic phase time was (37±7) min, and the intraoperative blood loss was (2 389±1 319) ml. No postoperative surgical complications were observed. The median postoperative length of hospital stay was 21(9-56) d. Moderate degree of acute rejection was respectively observed at postoperative 40 and 60 d in 2 patients, and the liver function was gradually restored to normal after the immunosuppressive therapy was strengthened. Among the 2 patients, 1 case suffered from stress ulcer and was cured after administration of antiacid and decreasing the dosage of hormone, the other case suffered from acute cholangitis after the restoration of acute rejection, and underwent secondary LT at postoperative 2 years. During the follow-up, 2 cases lost to follow-up and 3 died. Among the 3 patients, 2 died from multiple organ failure induced by septicopyemia at postoperative 32 and 97 d, and 1 died from respiratory system-related complications at postoperative 2 years.

Conclusions

LT is the most effective treatment for PBC at present. Active preoperative evaluation and processing, and strict surgical procedures are the keys to the success of surgery. Rational postoperative administration of immunosuppressive agents and other adjuvant drugs can effectively prevent the recurrence of PBC.

Key words: Liver cirrhosis, biliary, Liver transplantation, Ursodeoxycholic acidscopic

Runchen Miao, Kai Qu, Zeyu Li, Jianbin Bi, Jingxian Gu, Chang Liu. Application value of liver transplantation for primary biliary cirrhosis[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2017, 06(05): 397-400.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2017.05.014

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2017/V06/I05/397

References 22

[1]	Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis[J]. Lancet, 2015, 386(10003):1565-1575.
[2]	Webb GJ, Siminovitch KA, Hirschfield GM. The immunogenetics of primary biliary cirrhosis: a comprehensive review[J]. J Autoimmun, 2015, 64:42-52.
[3]	Singal AK, Fang X, Kaif M, et al. Primary biliary cirrhosis has high wait-list mortality among patients listed for liver transplantation[J]. Transpl Int, 2017, 30(5):454-462.
[4]	Weinmann A, Sattler T, Unold HP, et al. Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patients[J]. J Clin Gastroenterol, 2015, 49(5):438-447.
[5]	Parés A. Old and novel therapies for primary biliary cirrhosis[J]. Semin Liver Dis, 2014, 34(3):341-351.
[6]	Floreani A, Tanaka A, Bowlus C, et al. Geoepidemiology and changing mortality in primary biliary cholangitis[J]. J Gastroenterol, 2017, 52(6):655-662.
[7]	Chascsa D, Carey EJ, Lindor KD. Old and new treatments for primary biliary cholangitis[J]. Liver Int, 2017, 37(4):490-499.
[8]	Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J]. Gastroenterology, 2015, 148(4): 751-761, e8.
[9]	Trivedi PJ, Hirschfield GM, Gershwin ME. Obeticholic acid for the treatment of primary biliary cirrhosis[J]. Expert Rev Clin Pharmacol, 2016, 9(1):13-26.
[10]	Tanaka A, Ma X, Yokosuka O, et al. Autoimmune liver diseases in the Asia-Pacific region: proceedings of APASL symposium on AIH and PBC 2016[J]. Hepatol Int, 2016, 10(6):909-915.
[11]	Corpechot C. Primary biliary cirrhosis beyond ursodeoxycholic acid[J]. Semin Liver Dis, 2016, 36(1):15-26.
[12]	Czul F, Levy C. Novel therapies on primary biliary cirrhosis[J]. Clin Liver Dis, 2016, 20(1):113-130.
[13]	Yang H, Duan Z. Bile acids and the potential role in primary biliary cirrhosis[J]. Digestion, 2016, 94(3):145-153.
[14]	Zhu GQ, Shi KQ, Huang S, et al. Network meta-analysis of randomized controlled trials: efficacy and safety of UDCA-based therapies in primary biliary cirrhosis[J]. Medicine, 2015, 94(11): e609.
[15]	Dyson JK, Wilkinson N, Jopson L, et al. The inter-relationship of symptom severity and quality of life in 2 055 patients with primary biliary cholangitis[J]. Aliment Pharmacol Ther, 2016, 44(10):1039-1050.
[16]	Raczyńska J, Habior A, Pączek L, et al. Primary biliary cirrhosis in the era of liver transplantation[J]. Ann Transplant, 2014, 19:488-493.
[17]	Hosonuma K, Sato K, Yamazaki Y, et al. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia[J]. Am J Gastroenterol, 2015, 110(3): 423-431.
[18]	Gilroy RK, Lynch SV, Strong RW, et al. Confirmation of the role of the Mayo Risk Score as a predictor of resource utilization after orthotopic liver transplantation for primary biliary cirrhosis[J]. Liver Transpl, 2000, 6(6):749-752.
[19]	Žampachová V, Honsová E. Recurrence of primary diseases after liver transplantation[J]. Cesk Patol, 2015, 51(4):170-174.
[20]	Egawa H, Nakanuma Y, Maehara Y, et al. Disease recurrence plays a minor role as a cause for retransplantation after living-donor liver transplantation for primary biliary cirrhosis: a multicenter study in Japan[J]. Hepatol Res, 2013, 43(5):502-507.
[21]	Shiba H, Wakiyama S, Futagawa Y, et al. Switching from tacrolimus to cyclosporine A to prevent primary biliary cirrhosis recurrence after living-donor liver transplantation[J]. Int Surg, 2013, 98(2):156-159.
[22]	Bosch A, Dumortier J, Maucort-Boulch D, et al. Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence[J]. J Hepatol, 2015, 63(6):1449-1458.

Please choose a citation manager

Content to export